{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:50:37Z","timestamp":1794952237080,"version":"4.9.1"},"reference-count":57,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,8,16]],"date-time":"2004-08-16T00:00:00Z","timestamp":1092614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Aim<\/jats:bold> :\u2002In a predefined analysis, data were pooled from eight blinded, randomized, controlled trials, and separately from three long\u2010term, open\u2010label trials to determine the rate of upper gastrointestinal ulcer complications with the cyclo\u2010oxygenase\u20102 selective inhibitor, valdecoxib, vs. non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002In randomized, controlled trials, 7434 osteoarthritis and rheumatoid arthritis patients received placebo (<jats:italic>n<\/jats:italic>\u2003=\u2003973), valdecoxib 5\u201380\u2003mg daily (<jats:italic>n<\/jats:italic>\u2003=4362), or a non\u2010selective non\u2010steroidal anti\u2010inflammatory drug (naproxen, ibuprofen or diclofenac; <jats:italic>n<\/jats:italic>\u2003=2099) for 12\u201326\u2003weeks. In long\u2010term, open\u2010label trials, 2871 patients received valdecoxib 10\u201380\u2003mg daily for up to 1\u2003year. All potential events were reviewed by a blinded, independent review committee based on <jats:italic>a priori<\/jats:italic> definitions of ulcer complications (perforations, obstructions, bleeds).<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002In randomized, controlled trials, 19 of 955 potential events were adjudicated to be ulcer complications. Valdecoxib was associated with a significantly lower ulcer complication rate than non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs (0.68% vs. 1.96%, all patients; 0.29% vs. 2.08%, non\u2010aspirin users; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). In long\u2010term, open\u2010label trials, seven of 310 potential events were adjudicated to be ulcer complications; the annualized incidence for valdecoxib was 0.39% (seven of 1791 patient\u2010years) for all patients and 0.2% (three of 1472 patient\u2010years) for non\u2010aspirin users.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002Valdecoxib, including above recommended doses, is associated with a significantly lower rate of upper gastrointestinal ulcer complications than therapeutic doses of non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02118.x","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T14:38:16Z","timestamp":1093963096000},"page":"527-538","source":"Crossref","is-referenced-by-count":43,"title":["Reduced incidence of upper gastrointestinal ulcer complications with the COX\u20102 selective inhibitor, valdecoxib"],"prefix":"10.1111","volume":"20","author":[{"given":"J. L.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. F.","family":"Stenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,16]]},"reference":[{"key":"e_1_2_20_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89543-5"},{"key":"e_1_2_20_3_2","first-page":"8","article-title":"Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective 1997. Arthritis, Rheumatism, and Aging Medical Information System","volume":"51","author":"Singh G","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_20_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05974.x"},{"key":"e_1_2_20_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-10-787"},{"key":"e_1_2_20_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380103"},{"key":"e_1_2_20_7_2","volume-title":"NSAIDs: A Profile of Adverse Effects","author":"Borda IT","year":"1995"},{"key":"e_1_2_20_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00207-6"},{"key":"e_1_2_20_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91843-0"},{"key":"e_1_2_20_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03740.x"},{"key":"e_1_2_20_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J"},{"key":"e_1_2_20_12_2","first-page":"530","article-title":"Randomized placebo\u2010controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz A","year":"2002","journal-title":"J Fam Pract"},{"key":"e_1_2_20_13_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with rheumtoid arthrtits: a multicenter trial [Abstract]","volume":"96","author":"Goldstein JL","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_20_14_2","article-title":"Comparative gastroduodenal mucosal effects of valdecoxib, a potent COX\u20102 specific inhibitor, compared with naproxen and placebo [Abstract]","volume":"49","author":"Goldstein JL","year":"2001","journal-title":"Gut"},{"key":"e_1_2_20_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01691.x"},{"key":"e_1_2_20_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01407.x"},{"key":"e_1_2_20_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01007.x"},{"key":"e_1_2_20_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00318-5"},{"key":"e_1_2_20_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00529.x"},{"key":"e_1_2_20_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.3.1126"},{"key":"e_1_2_20_21_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.53.082901.103952"},{"key":"e_1_2_20_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.7.913"},{"key":"e_1_2_20_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.25.12013"},{"key":"e_1_2_20_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.52.33157"},{"key":"e_1_2_20_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8690211"},{"key":"e_1_2_20_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6254151"},{"key":"e_1_2_20_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V"},{"key":"e_1_2_20_28_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1963.sp007185"},{"key":"e_1_2_20_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajem.2002.32635"},{"key":"e_1_2_20_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_20_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"e_1_2_20_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1333"},{"key":"e_1_2_20_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_20_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_20_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02194.x"},{"key":"e_1_2_20_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1929"},{"key":"e_1_2_20_37_2","first-page":"S318","article-title":"A lower incidence of upper\u2010GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs)","volume":"44","author":"Harper S","year":"2001","journal-title":"Arthritis & Rheumatism"},{"key":"e_1_2_20_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.26.15810"},{"key":"e_1_2_20_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1921"},{"key":"e_1_2_20_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.8.3228"},{"key":"e_1_2_20_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-3-10"},{"key":"e_1_2_20_42_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000282"},{"key":"e_1_2_20_43_2","first-page":"1623","article-title":"A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"29","author":"Matsumoto AK","year":"2002","journal-title":"J Rheumatol."},{"key":"e_1_2_20_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2001.0510"},{"key":"e_1_2_20_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.9.1008"},{"key":"e_1_2_20_46_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.11.1095"},{"key":"e_1_2_20_47_2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0091270003252234","article-title":"The COX\u20102 specific inhibitor valdecoxib does not impair platelet function in the elderly: results of a randomized controlled trial","volume":"43","author":"Leese PT","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_20_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008766"},{"key":"e_1_2_20_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001224"},{"key":"e_1_2_20_50_2","first-page":"558","article-title":"Etoricoxib (MK\u20100663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase\u20102","volume":"296","author":"Riendeau D","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_20_51_2","first-page":"1876","article-title":"Upper gastrointestinal tolerability of celecoxib, a COX\u20102 specific inhibitor, compared to naproxen and placebo","volume":"27","author":"Bensen WG","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_20_52_2","first-page":"3449","article-title":"GI events leading to death in association with celecoxib and rofecoxib","volume":"96","author":"Weaver J","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_20_53_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm990577v"},{"key":"e_1_2_20_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02085-9"},{"key":"e_1_2_20_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200210000-00011"},{"issue":"1","key":"e_1_2_20_56_2","article-title":"Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX\u20102 specific inhibitor, compared with conventional NSAIDs: The SUCCESS\u20101 trial","volume":"60","author":"Goldstein JL","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_20_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199701000-00003"},{"key":"e_1_2_20_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90185-6"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02118.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02118.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02118.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:12:54Z","timestamp":1697231574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02118.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,16]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02118.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02118.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,16]]}}}